Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases
From this real-world analysis, Italian patients with MIBC emerged as a population of elderly subjects (> 75 years) burdened by comorbidities. Treatment choice was influenced by other factors rather than cisplatin eligibility since only 11% of patients with CrCl ≥ 60 ml/min in 2018 and 20% in 2022 were treated before cystectomy, highlighting a scenario of low adherence to guidelines with underutilization of neoadjuvant chemotherapy.
Authors
- Lorenzo Antonuzzo (ORCID: https://orcid.org/0000-0003-3349-5604)
- Valentina Perrone (ORCID: https://orcid.org/0000-0001-5018-490X)
- Daniela Castelletti
- Paolo Luraghi (ORCID: https://orcid.org/0000-0003-2379-5195)
- Stefania Mazzoni
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- Serena Losi (ORCID: https://orcid.org/0000-0002-2205-5577)
- Matteo Risi
Institutions
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- AstraZeneca (Italy) (IT)
- University of Florence (IT)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1007/s12325-025-03420-3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Regione Umbria